FPR2 and COVID-19: In the context of thromobinflammation and the possible insights for therapeutic strategies for COVID‐19 treatments, we recently discovered that targeting the AnxA1/Fpr2/ALX pathway promotes thromboinflammation resolution by altering both the platelet phenotype (from pro‐pathogenic to regulatory) (Senchenkova, Ansari, et al., 2019) and the pathological neutrophil phenotype (from a pro‐NETotic to pro‐apoptotic) (Ansari et al., 2021).